A study involving 65 patients with unresectable HCC or advanced cholangiocarcinoma, who switched to PD-1 inhibitors following first-line chemotherapy (gemcitabine plus cisplatin), indicated that the composition of gut microbiota is significantly related to the clinical responses of immunotherapy. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.